Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 68Ga-Pentixafor PET/CT demonstrating higher CXCR4 density in small cell lung carcinoma than in non-small cell variant.

Literature DB >> 28110347

68Ga-Pentixafor PET/CT demonstrating higher CXCR4 density in small cell lung carcinoma than in non-small cell variant.

Ankit Watts¹, Baljinder Singh², Rajender Basher¹, Harmandeep Singh¹, Amanjit Bal¹, Rakesh Kapoor¹, Sunil K Arora¹, Hans J Wester¹, B R Mittal¹, D Behera¹.

Abstract

Entities: Chemical Disease Gene

Mesh：

Substances：

Year: 2017 PMID： 28110347 DOI： 10.1007/s00259-017-3622-7

Source DB: PubMed Journal: Eur J Nucl Med Mol Imaging ISSN： 1619-7070 Impact factor: 9.236

× No keyword cloud information.

5 in total

1. First-in-Human Experience of CXCR4-Directed Endoradiotherapy with 177Lu- and 90Y-Labeled Pentixather in Advanced-Stage Multiple Myeloma with Extensive Intra- and Extramedullary Disease.

Authors: Ken Herrmann; Margret Schottelius; Constantin Lapa; Theresa Osl; Andreas Poschenrieder; Heribert Hänscheid; Katharina Lückerath; Martin Schreder; Christina Bluemel; Markus Knott; Ulrich Keller; Andreas Schirbel; Samuel Samnick; Michael Lassmann; Saskia Kropf; Andreas K Buck; Hermann Einsele; Hans-Juergen Wester; Stefan Knop
Journal: J Nucl Med Date: 2015-11-12 Impact factor: 10.057

2. First Experience with Chemokine Receptor CXCR4-Targeted PET Imaging of Patients with Solid Cancers.

Authors: Tibor Vag; Carlos Gerngross; Peter Herhaus; Matthias Eiber; Kathrin Philipp-Abbrederis; Frank-Philipp Graner; Johannes Ettl; Ulrich Keller; Hans-Jürgen Wester; Markus Schwaiger
Journal: J Nucl Med Date: 2016-01-14 Impact factor: 10.057

3. PET imaging of CXCR4 receptors in cancer by a new optimized ligand.

Authors: Oliver Demmer; Eleni Gourni; Udo Schumacher; Horst Kessler; Hans-Jürgen Wester
Journal: ChemMedChem Date: 2011-07-20 Impact factor: 3.466

Review 4. CXCR4/CXCL12 axis in non small cell lung cancer (NSCLC) pathologic roles and therapeutic potential.

Authors: Ori Wald; Oz M Shapira; Uzi Izhar
Journal: Theranostics Date: 2013-01-13 Impact factor: 11.556

5. [68Ga]Pentixafor-PET/CT for imaging of chemokine receptor 4 expression in small cell lung cancer--initial experience.

Authors: Constantin Lapa; Katharina Lückerath; Martina Rudelius; Jan-Stefan Schmid; Alexander Schoene; Andreas Schirbel; Samuel Samnick; Theo Pelzer; Andreas K Buck; Saskia Kropf; Hans-Jürgen Wester; Ken Herrmann
Journal: Oncotarget Date: 2016-02-23

5 in total

1. [¹⁷⁷Lu]pentixather: Comprehensive Preclinical Characterization of a First CXCR4-directed Endoradiotherapeutic Agent.

Authors: Margret Schottelius; Theresa Osl; Andreas Poschenrieder; Frauke Hoffmann; Seval Beykan; Heribert Hänscheid; Andreas Schirbel; Andreas K Buck; Saskia Kropf; Markus Schwaiger; Ulrich Keller; Michael Lassmann; Hans-Jürgen Wester
Journal: Theranostics Date: 2017-06-11 Impact factor: 11.556

68Ga-Pentixafor PET/CT demonstrating higher CXCR4 density in small cell lung carcinoma than in non-small cell variant.

1. First-in-Human Experience of CXCR4-Directed Endoradiotherapy with 177Lu- and 90Y-Labeled Pentixather in Advanced-Stage Multiple Myeloma with Extensive Intra- and Extramedullary Disease.

2. First Experience with Chemokine Receptor CXCR4-Targeted PET Imaging of Patients with Solid Cancers.

3. PET imaging of CXCR4 receptors in cancer by a new optimized ligand.

Review 4. CXCR4/CXCL12 axis in non small cell lung cancer (NSCLC) pathologic roles and therapeutic potential.

5. [68Ga]Pentixafor-PET/CT for imaging of chemokine receptor 4 expression in small cell lung cancer--initial experience.

1. [¹⁷⁷Lu]pentixather: Comprehensive Preclinical Characterization of a First CXCR4-directed Endoradiotherapeutic Agent.

2. A new class of PentixaFor- and PentixaTher-based theranostic agents with enhanced CXCR4-targeting efficiency.

3. Automated Radiosynthesis, Quality Control, and Biodistribution of Ga-68 Pentixafor: First Indian Experience.

Review 4. In Vivo Targeting of CXCR4-New Horizons.

5. C-terminal-modified LY2510924: a versatile scaffold for targeting C-X-C chemokine receptor type 4.